ClinicalTrials.gg
CompletedNCT06973681Updated Oct 13, 2026

A Study of BGM0504 Evaluating Weight Loss in Overweight or Obese Chinese Subjects

A Phase 2 interventional study of BGM0504 and BGM0504 in Overweight or Obesity, sponsored by BrightGene Bio-Medical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by BrightGene Bio-Medical Technology Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2024, 2 years 2 months ago, and no results have been posted to the registry.
  • Registered 1 year 7 months after the study started (first participant enrolled Oct 2023, registered May 2025).
Updated Oct 13, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing BGM0504 in Obesity — none open to participants now, none under way, none of them phase 3. BGM0504 · Obesity.

Enrollment
3rd of 10
120 · median 78
Started
2023
the only one that year
Phase 2
3 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
8 of 10
BrightGene Bio-Medical Technology Co., Ltd.

Among the 10 studies testing BGM0504 in Obesity, this one is the 3rd largest by enrollment, is the only one that started in 2023, is one of 3 in phase 2, and was the 6th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

None of the 10 studies testing BGM0504 in Obesity is open now. The open studies under Obesity, anywhere →

Where they have run

About BGM0504

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing BGM0504 in Obesity as a file.
02

Study summary

To assess the effect of BGM0504 injection versus placebo on weight loss in overweight or obese subjects after 24 weeks of treatment.

03

Conditions studied

  • Overweight or Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 120 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

BrightGene Bio-Medical Technology Co., Ltd. is the lead sponsor of 18 studies on the registry; 3 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • ≥ 28.0 kg/m2 or 24.0 ≤ BMI \< 28.0 kg/m2 with at least 1 weight-related comorbidity at screening visit;
  • Controlled by diet and exercise alone for at least 12 weeks prior to Screening with \<5.0% change in body weight and able to continue the original diet and exercise for weight control during the trial.

Exclusion Criteria:● Those who have used weight loss drugs within 12 weeks before screening;

  • Previous diagnosis of type 1 or type 2 diabetes mellitus;
  • History of acute or chronic pancreatitis, or pancreatic injury;
  • History of thyroid C-cell carcinoma, MEN (multiple endocrine adenomatosis) 2A or 2B, or relevant family history;
  • Subjects with uncontrolled hypertension after treatment (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥ 100 mmHg at screening) or untreated blood pressure meeting the above criteria at screening;
  • Concomitant thyroid dysfunction that cannot be controlled at a stable drug dose atscreening, or abnormalities in thyroid function test results at screening that require initiation of therapy;
  • At Screening, abdominal ultrasound indicated calculus gallbladder and polyps, or presence of clinical symptoms of gallbladder disease at Screening;
  • Pregnant or breastfeeding women.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    5 mg BGM0504

    5 milligrams (mg) BGM0504 administered subcutaneously (SC) once a week.

    Drug: BGM0504

  • Experimental
    10 mg BGM0504

    10 mg BGM0504 administered SC once a week.

    Drug: BGM0504

  • Experimental
    15 mg BGM0504

    15 mg BGM0504 administered SC once a week.

    Drug: BGM0504

  • Placebo comparator
    Placebo

    Placebo administered SC once a week.

    Drug: Placebo

Interventions

07

What researchers measure

Primary outcomes

  1. Percentage change in body weight

    Percentage change from baseline in body weight after 24 weeks of treatment.

    Time frame: Week 0 to Week 24

Secondary outcomes

  1. Proportion of Subjects with weight loss of ≥5%

    Proportion of Subjects with weight loss of ≥5% from baseline in body weight after 24 weeks of treatment

    Time frame: Week 0 to Week 24

  2. Change from baseline in waist circumference

    Change from baseline in waist circumference after 24 weeks of treatment

    Time frame: Week 0 to Week 24

  3. Change from baseline in BMI

    Change from baseline in BMI after 24 weeks of treatment

    Time frame: Week 0 to Week 24

  4. Change from baseline in fasting plasma glucose (FPG)

    Change from baseline in fasting plasma glucose (FPG) after 24 weeks of treatment

    Time frame: Week 0 to Week 24

08

Study locations

1 site
  • The Third Xiangya Hospital of Central South University
    Changsha, China
09

References and documents

Publications

  • Ji L, Yang G, Huang Y, Ding H, Xie D, Jiang X, Yuan X, Cao Z, Chan Z, Zhang H, Yuan J. Effectiveness, Safety and Pharmacokinetics of BGM0504, a Dual GLP-1/GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Obes Metab. 2026 Sep 17. doi: 10.1111/dom.71193. Online ahead of print. PubMed 42755112 ↗
10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Sep 2024, 11 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 11 months is close to that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2025
First posted
May 15, 2025
StartActual
Oct 13, 2023
Primary completionActual
Sep 13, 2024
CompletionActual
Sep 13, 2024
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 criterion edited, 9 added, 1 removed
What changed in the criteria
  • AddedBMI ≥ 28.0 kg/m2 or 24.0 ≤ BMI < 28.0 kg/m2 with at least 1 weight-related comorbidity at screening visit;
  • Edited1. BMI ≥ 28.0 kg/m2 or 24.0 ≤ BMI < 28.0 kg/m2 with at least 1 weight-related comorbidity at screening visit; 2.Controlled by diet and exercise alone for at least 12 weeks prior to Screening with <5.0% change in body weight and able to continue the original diet and exercise for weight control during the trial.
  • RemovedExclusion Criteria:1.Those who have used weight loss drugs within 12 weeks before screening; 2. Previous diagnosis of type 1 or type 2 diabetes mellitus; 3. History of acute or chronic pancreatitis, or pancreatic injury; 4. History of thyroid C-cell carcinoma, MEN (multiple endocrine adenomatosis) 2A or 2B, or relevant family history; 5. Subjects with uncontrolled hypertension after treatment (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥ 100 mmHg at screening) or untreated blood pressure meeting the above criteria at screening; 6. Concomitant thyroid dysfunction that cannot be controlled at a stable drug dose atscreening, or clinically significant abnormalities in thyroid function test results at screening that require initiation of therapy; 7. At Screening, abdominal ultrasound indicated calculus gallbladder and polyps, or presence of clinical symptoms of gallbladder disease at Screening; 8. Pregnant or breastfeeding women.
  • AddedExclusion Criteria:● Those who have used weight loss drugs within 12 weeks before screening;
  • AddedPrevious diagnosis of type 1 or type 2 diabetes mellitus;
  • AddedHistory of acute or chronic pancreatitis, or pancreatic injury;
  • AddedHistory of thyroid C-cell carcinoma, MEN (multiple endocrine adenomatosis) 2A or 2B, or relevant family history;
  • AddedSubjects with uncontrolled hypertension after treatment (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥ 100 mmHg at screening) or untreated blood pressure meeting the above criteria at screening;
  • AddedConcomitant thyroid dysfunction that cannot be controlled at a stable drug dose atscreening, or clinically significant abnormalities in thyroid function test results at screening that require initiation of therapy;
  • AddedAt Screening, abdominal ultrasound indicated calculus gallbladder and polyps, or presence of clinical symptoms of gallbladder disease at Screening;
  • AddedPregnant or breastfeeding women.
Oct 13, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42755112 ↗
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42755112 ↗
    Eligibility 1 criterion edited, 9 added, 1 removed
    What changed in the criteria
    • AddedBMI ≥ 28.0 kg/m2 or 24.0 ≤ BMI < 28.0 kg/m2 with at least 1 weight-related comorbidity at screening visit;
    • Edited1. BMI ≥ 28.0 kg/m2 or 24.0 ≤ BMI < 28.0 kg/m2 with at least 1 weight-related comorbidity at screening visit; 2.Controlled by diet and exercise alone for at least 12 weeks prior to Screening with <5.0% change in body weight and able to continue the original diet and exercise for weight control during the trial.
    • RemovedExclusion Criteria:1.Those who have used weight loss drugs within 12 weeks before screening; 2. Previous diagnosis of type 1 or type 2 diabetes mellitus; 3. History of acute or chronic pancreatitis, or pancreatic injury; 4. History of thyroid C-cell carcinoma, MEN (multiple endocrine adenomatosis) 2A or 2B, or relevant family history; 5. Subjects with uncontrolled hypertension after treatment (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥ 100 mmHg at screening) or untreated blood pressure meeting the above criteria at screening; 6. Concomitant thyroid dysfunction that cannot be controlled at a stable drug dose atscreening, or clinically significant abnormalities in thyroid function test results at screening that require initiation of therapy; 7. At Screening, abdominal ultrasound indicated calculus gallbladder and polyps, or presence of clinical symptoms of gallbladder disease at Screening; 8. Pregnant or breastfeeding women.
    • AddedExclusion Criteria:● Those who have used weight loss drugs within 12 weeks before screening;
    • AddedPrevious diagnosis of type 1 or type 2 diabetes mellitus;
    • AddedHistory of acute or chronic pancreatitis, or pancreatic injury;
    • AddedHistory of thyroid C-cell carcinoma, MEN (multiple endocrine adenomatosis) 2A or 2B, or relevant family history;
    • AddedSubjects with uncontrolled hypertension after treatment (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥ 100 mmHg at screening) or untreated blood pressure meeting the above criteria at screening;
    • AddedConcomitant thyroid dysfunction that cannot be controlled at a stable drug dose atscreening, or clinically significant abnormalities in thyroid function test results at screening that require initiation of therapy;
    • AddedAt Screening, abdominal ultrasound indicated calculus gallbladder and polyps, or presence of clinical symptoms of gallbladder disease at Screening;
    • AddedPregnant or breastfeeding women.
    + 1 other change: index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06973681
Responsible party
Sponsor
First posted
May 15, 2025
Start date
Oct 13, 2023
Primary completion
Sep 13, 2024
Completion
Sep 13, 2024
Last update
Oct 13, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BGM0504

Start the discussion